157 related articles for article (PubMed ID: 19007110)
21. FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models.
Takeuchi M; Hirasawa A; Hara T; Kimura I; Hirano T; Suzuki T; Miyata N; Awaji T; Ishiguro M; Tsujimoto G
Br J Pharmacol; 2013 Apr; 168(7):1570-83. PubMed ID: 22639973
[TBL] [Abstract][Full Text] [Related]
22. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
23. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
24. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).
Sparks SM; Chen G; Collins JL; Danger D; Dock ST; Jayawickreme C; Jenkinson S; Laudeman C; Leesnitzer MA; Liang X; Maloney P; McCoy DC; Moncol D; Rash V; Rimele T; Vulimiri P; Way JM; Ross S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3100-3. PubMed ID: 24881566
[TBL] [Abstract][Full Text] [Related]
25. Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ-selective partial agonists by disruption of molecular planarity/symmetry.
Kasuga J; Ishikawa M; Yonehara M; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2010 Oct; 18(20):7164-73. PubMed ID: 20843696
[TBL] [Abstract][Full Text] [Related]
26. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
27. Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.
Otake K; Azukizawa S; Takeda S; Fukui M; Kawahara A; Kitao T; Shirahase H
Chem Pharm Bull (Tokyo); 2015; 63(12):998-1014. PubMed ID: 26633022
[TBL] [Abstract][Full Text] [Related]
28. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R
Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611
[TBL] [Abstract][Full Text] [Related]
29. 3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA.
Liao C; Xie A; Zhou J; Shi L; Li Z; Lu XP
J Mol Model; 2004 Jun; 10(3):165-77. PubMed ID: 15022104
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
Sato A; Dodo K; Makishima M; Hashimoto Y; Sodeoka M
Bioorg Med Chem Lett; 2013 May; 23(10):3013-7. PubMed ID: 23566516
[TBL] [Abstract][Full Text] [Related]
31. The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.
Holmes IP; Gaines S; Watson SP; Lorthioir O; Walker A; Baddeley SJ; Herbert S; Egan D; Convery MA; Singh OM; Gross JW; Strelow JM; Smith RH; Amour AJ; Brown D; Martin SL
Bioorg Med Chem Lett; 2009 Oct; 19(19):5760-3. PubMed ID: 19703773
[TBL] [Abstract][Full Text] [Related]
32. GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.
Carullo G; Mazzotta S; Vega-Holm M; Iglesias-Guerra F; Vega-Pérez JM; Aiello F; Brizzi A
J Med Chem; 2021 Apr; 64(8):4312-4332. PubMed ID: 33843223
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
34. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of APTCs (aminopyrrolidinetricarboxylic acids): identification of a new group III metabotropic glutamate receptor selective agonist.
Schann S; Menet C; Arvault P; Mercier G; Frauli M; Mayer S; Hubert N; Triballeau N; Bertrand HO; Acher F; Neuville P
Bioorg Med Chem Lett; 2006 Sep; 16(18):4856-60. PubMed ID: 16828551
[TBL] [Abstract][Full Text] [Related]
36. 8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.
Funke M; Thimm D; Schiedel AC; Müller CE
J Med Chem; 2013 Jun; 56(12):5182-97. PubMed ID: 23713606
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
[TBL] [Abstract][Full Text] [Related]
38. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
39. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
Laghezza A; Pochetti G; Lavecchia A; Fracchiolla G; Faliti S; Piemontese L; Di Giovanni C; Iacobazzi V; Infantino V; Montanari R; Capelli D; Tortorella P; Loiodice F
J Med Chem; 2013 Jan; 56(1):60-72. PubMed ID: 23171045
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
